NEOS Investment Management LLC Has $2.62 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)

NEOS Investment Management LLC raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 43.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,040 shares of the biotechnology company’s stock after acquiring an additional 5,736 shares during the period. NEOS Investment Management LLC’s holdings in Ascendis Pharma A/S were worth $2,621,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Legato Capital Management LLC boosted its stake in Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 134 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 214 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 328 shares during the period.

Analysts Set New Price Targets

Several research firms have issued reports on ASND. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 18th. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Cantor Fitzgerald raised their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. The Goldman Sachs Group boosted their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, Evercore ISI raised their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND opened at $154.68 on Friday. The company has a market capitalization of $9.39 billion, a PE ratio of -21.79 and a beta of 0.62. The company’s fifty day moving average is $144.16 and its 200-day moving average is $137.01. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.